



(86) Date de dépôt PCT/PCT Filing Date: 2005/06/03
(87) Date publication PCT/PCT Publication Date: 2006/01/12
(45) Date de délivrance/Issue Date: 2013/02/19
(85) Entrée phase nationale/National Entry: 2006/12/28
(86) N° demande PCT/PCT Application No.: EP 2005/005981
(87) N° publication PCT/PCT Publication No.: 2006/002726
(30) Priorité/Priority: 2004/06/30 (DE10 2004 031 656.2)


(51) Cl.Int./Int.Cl. *C07D 491/04* (2006.01),
A61K 31/4355 (2006.01), *A61K 31/436* (2006.01),
C07D 221/00 (2006.01), *C07D 317/00* (2006.01),
C07D 319/00 (2006.01)

(72) Inventeurs/Inventors:
SCHIEMANN, KAI, DE;
BRUGE, DAVID, DE;
BUCHSTALLER, HANS-PETER, DE;
FINSINGER, DIRK, DE;
STAEHLE, WOLFGANG, DE;
AMENDT, CHRISTIANE, DE;

...

(73) Propriétaire/Owner:

(54) Titre : TETRAHYDROQUINOLINE
(54) Title: TETRAHYDROQUINOLINES



(57) Abrégé/Abstract:

Disclosed are compounds of formula (I) (see formula I), wherein W, R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ have the meanings indicated in claim 1. Said compounds can be used for the treatment of tumors, among other things.



(72) Inventeurs(suite)/Inventors(continued): EMDE, ULRICH, DE; ZENKE, FRANK, DE


(73) Propriétaires(suite)/Owners(continued):MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG, DE

(74) Agent: FETHERSTONHAUGH & CO.

26474-1066

ABSTRACT

Disclosed are compounds of formula (I)



wherein W, R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ have the meanings indicated in claim 1.

5 Said compounds can be used for the treatment of tumors, among other things.

Tetrahydroquinolines

BACKGROUND OF THE INVENTION

The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

The present invention relates to compounds and to the use of compounds of diseases in which the inhibition, regulation and/or modulation of mitotic motor proteins, in particular the mitotic motor protein Eg5, plays a role, furthermore to pharmaceutical compositions which comprise these compounds.

In detail, the present invention relates to compounds of the formula I which which preferably inhibit, regulate and/or modulate one or more mitotic motor proteins, to compositions which comprise these compounds, and to methods for the use thereof for the treatment of diseases and complaints such as angiogenesis, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, choroidal neovascularisation and diabetic retinopathy, inflammatory diseases, arthritis, neurodegeneration, restenosis, wound healing or transplant rejection. In particular, the compounds according to the invention are suitable for the therapy or prophylaxis of cancer diseases.

During mitosis, various kinesins regulate the formation and dynamics of the spindle apparatus, which is responsible for correct and coordinated alignment and separation of the chromosomes. It has been observed that specific inhibition of a mitotic motor protein – Eg5 – results in collapse of the spindle fibres. The result of this is that the chromosomes can no longer be distributed correctly over the daughter cells. This results in

26474-1066

- 2 -

mitotic arrest and can thus cause cell death. Upregulation of the motor protein Eg5 has been described, for example, in tissue from breast lung and colon tumours. Since Eg5 takes on a mitosis-specific function, it is principally rapidly dividing cells and not fully differentiated cells that are affected by Eg5 inhibition. In addition, Eg5 regulates exclusively the movement of mitotic microtubuli (spindle apparatus) and not that of the cytoskeleton. This is crucial for the side-effect profile since, for example, neuropathies, as observed in the case of TaxolTM, do not occur or only do so to a weakened extent. The inhibition of Eg5 by organic molecules is therefore a relevant therapy concept for the treatment of malignant tumours.

In general, old solid and non-solid tumours come treated with the compounds of the formula I, such as, for example, monocytic leukaemia, brain, urogenital, lymphatic system, stomach, laryngeal and lung carcinoma, including lung adenocarcinoma and small-cell lung carcinoma. Further examples include prostate, pancreatic and breast carcinoma.

Surprisingly, it has been found that the compounds according to the invention effect specific inhibition of mitotic motor proteins, in particular Eg5. The compounds according to the invention preferably exhibit an advantageous biological activity which can easily be detected in the assays described herein, for example. In such, the compounds according to the invention preferably exhibit and cause an inhibiting effect, which is usually documented by IC₅₀ values in a suitable range, preferably in the micromolar range and more preferably in the nanomolar range.

As discussed herein, effects of the compound according to the invention are relevant to various diseases. Accordingly, the compounds according to the invention are useful in the prophylaxis and/or treatment of diseases which are influenced by inhibition of one or more mitotic motor proteins, in particular Eg5.

The present invention therefore relates to compounds according to the invention as medicaments and/or medicament active ingredients in the treatment and/or prophylaxis of the said diseases and to the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and/or prophylaxis of the said diseases, and also to a method for the treatment of the said diseases comprising the administration of one or more compounds according to the invention to a patient in need of such an administration.

It can be shown that the compounds according to the invention have an advantageous effect in a xenotransplant tumour model.

The host or patient can belong to any mammal species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cattle, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for the treatment of a human disease.

The susceptibility of a certain cell to treatment with the compounds according to the invention can be determined by testing in vitro. Typically, a culture of the cell is combined with a compound according to the invention at various concentrations for a period which is sufficient to enable the active agents to induce cell death or inhibit migration, usually between approximately one hour and one week. For testing in vitro, cultivated cells from a biopsy sample can be used. The viable cells remaining after the treatment are then counted.

The dose varies depending on the specific compound used, the specific disease, the patient status, etc. Typically, a therapeutic dose is sufficient considerably to reduce the undesired cell population in the target tissue, while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example at


least about a 50% reduction in the cell burden, and can be continued until essentially no undesired cells are detected in the body.

PRIOR ART

Similar compounds are described, for example, in Tetrahedron Lett. **1988**, 29, 5855-5858, Tetrahedron Lett. **2003**, 44, 217-219, J. Org. Chem. **1997**, 62, 4880-4882, J. Org. Chem. **1999**, 64, 6462-6467, Chem. Lett. **1995**, 423-424, J. Org. Chem. **2000**, 65, 5009-5013, Chem. Lett. **2003**, 32, 222-223, US2003149069A1, but are not mentioned in connection with cancer treatments and/or do not contain the features that are essential to the invention.

SUMMARY OF THE INVENTION

The invention relates to compounds of the formula I



in which



W denotes CH or N,

R^1 , R^2 , R^3 , independently of one another, denote H, A, aryl, heteroaryl, Hal, $-(CY_2)_n-SA$, $-(CY_2)_n-SCF_3$, $-(CY_2)_n-SCN$, $-(CY_2)_n-CF_3$, $-(CY_2)_n-OCF_3$, cycloalkyl, $-SCH_3$, $-SCN$, $-CF_3$, $-OCF_3$, $-OA$, $-(CY_2)_n-OH$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$, $-(CY_2)_n-Hal$, $-(CY_2)_n-NR_2$, $(CY_2)_n-OA$, $(CY_2)_n-OCOA$, $-SCF_3$, $(CY_2)_n-CONR_2$, $-(CY_2)_n-NHCOA$, $-(CY_2)_n-NHSO_2A$,



	Y	denotes H, A, Hal
	A	denotes alkyl or cycloalkyl,
5	Hal	denotes F, Cl, Br or I
	R	denotes H or A, in the case of geminal radicals R together also $-(CH_2)_5-$, $-(CH_2)_4-$ or $-(CH_2)_2-NR-(CH_2)_2$,
10	R^4, R^5	together denote $-X(CH_2)_2X-$, $-X(CR_2)X-$, $-XCH(CH_2OR)X-$, $-XCH(CH_2OR)CR_2X-$, $-XCR_2CH(CH_2OR)X-$, $-XCH(CH_2NR_2)X-$, $-XCH(CH_2NR_2)CR_2X-$, 15 $-XCR_2CH(CH_2NR_2)X-$, $-OCH_2CH_2O-$, $-X(CH_2)_2X-$, $-XCHQCR_2X$, $-XCR_2CHQX-$, $-XCR_2)X-$, $-XCH(CH_2OR)X-$, $-XCH(CH_2OR)CR_2X-$, $-XCH(CH_2NR_2)X-$, $-XCH(CH_2NR_2)CR_2X-$, $-OCH_2CH_2O-$, $-X-\overset{\overset{ }{X}}{C}-X-$,
20	Q	denotes CH_2Hal , CHO , COR^a , CH_2R^a , CH_2OCOR^a , CH_2NCOR^1 , $CH_2N(R^1)_2$, CH_2OR^1 , $CH_2OCON(R^1)_2$, 25 CH_2OCOOR^1 , $CH_2NHCON(R^1)_2$, $CH_2NHCOOR^1$,
30		
35		

26474-1066



- 6 -

 R^a denotes



5





10







15



20



$$(CH_2)_n-[X(CH_2)_n]_m-N\text{---}\text{Cyclopentyl}---NR_2$$

$$(\text{CH}_2)_n\text{---}[\text{X}(\text{CH}_2)_n]_m\text{---N} \begin{array}{c} \diagup \text{N} \diagdown \\ \diagdown \text{N} \diagup \end{array}$$
*c1nc2c(ncn2C[C@@H](C1=O)N(C(=O)OCC3=CC=CC=C3)C(=O)OCC4=CC=CC=C4)cc5ccccc5*c1nc(C[C@@H](C(=O)N)N(C(=O)OCC(R1))c2ncn12)c3ncn3
$$(\text{CH}_2)_n\text{---}[\text{X}(\text{CH}_2)_n]_m\text{---N} \begin{array}{c} \diagup \text{N} \\ \diagdown \text{N} \end{array}$$


OR, NHR₂, NR₂OR, NHR₂, NR₂, NR(CH₂)_n-aryl,
 NR(CH₂)_nOR, COOR, N-pyrrolidone radical, OCOR,
 NR(CH₂)_nNR₂, N[(CH₂)_nNR₂]CO(CH₂)_n-aryl,
 5 N[(CH₂)_nNHCOOR]CO-aryl, R¹, N[CH₂(CH₂)_nOR]₂,
 NR(CH₂)_nNCOOR, X(CH₂)_nX(CH₂)_nXR, NR(CH₂)_nX(CH₂)_nOH,
 NR(CH₂)_nO(CH₂)_nOH, (CH₂)_nCOOR, O(CO)NR(CH₂)_nOR,
 O(CO)(CH₂)_nNR₂, NR(CH₂)_nNR₂, N[(CH₂)_nNR₂]CO(CH₂)_n-
 10 aryl, N[(CH₂)_nXR]CO(CH₂)_nAryl, N[(CH₂)_nXR]CO(CH₂)_n-
 heteroaryl, N[(CH₂)_nNR₂]CO(CH₂)_n-heteroaryl,
 N[(CH₂)_nNR₂]CO(CH₂)_nR¹, N(R)(CH₂)_nN(R)COOR,
 XCOO(CH₂)_nNR₂, OSO₂A, OSO₂CF₃, OSO₂Ar, OCONR₂,
 15 OCH₂(CH₂)_nNR₂

Z denotes CH₂, X, CHCONH₂, CH(CH₂)_nNRCOOR,
 CHNRCOOR, NCO, CH(CH₂)_nCOOR, NCOOR,
 CH(CH₂)_nOH, N(CH₂)_nOH, CHNH₂, CH(CH₂)_nNR₂,
 20 CH(CH₂)_nNR₂, C(OH)R, CHNCOR, CH(CH₂)_n-aryl, CH(CH₂)_n-
 heteroaryl, CH(CH₂)_nR¹, N(CH₂)_nCOOR, CH(CH₂)_nX(CH₂)_n-
 aryl, CH(CH₂)_nX(CH₂)_n-heteroaryl, N(CH₂)_nCONR₂,
 XCONR(CH₂)_nNR₂, N[(CH₂)_nXCOOR]CO(CH₂)_n-aryl,
 25 N[(CH₂)_nXR]CO(CH₂)_n-aryl, N[(CH₂)_nXR]CO(CH₂)_nX-aryl,
 N[(CH₂)_nXR]SO₂(CH₂)_n-aryl, N[(CH₂)_nNRCOOR]CO(CH₂)_n-
 aryl, N[(CH₂)_nNR₂]CO(CH₂)_n-aryl, N[(CH₂)_nNR₂]CO(CH₂)_nNR-
 aryl, N[(CH₂)_nNR₂]SO₂(CH₂)_n-aryl, N[(CH₂)_nXR]CO(CH₂)_n-
 30 heteroaryl, N[(CH₂)_nXR]CO(CH₂)_nX-heteroaryl,
 N[(CH₂)_nXR]SO₂(CH₂)_n-heteroaryl,
 N[(CH₂)_nNRCOOR]CO(CH₂)_n-heteroaryl,
 N[(CH₂)_nNR₂]CO(CH₂)_n-heteroaryl,
 N[(CH₂)_nNR₂]CO(CH₂)_nNR-heteroaryl,
 35 N[(CH₂)_nNR₂]SO₂(CH₂)_n-heteroaryl, O(CH₂)_nNR₂,
 X(CH₂)_nNR₂, NCO(CH₂)_nNR₂,

26474-1066

- 9 -

X denotes O, S or NR

R^6 denotes aryl or heteroaryl, each of which is unsubstituted or mono- or polysubstituted by aryl or heteroaryl, each of which may be substituted by Hal, NO_2 , CN, A, OR, OCOR, NR_2 , CF_3 , OCF_3 , $OCH(CF_3)_2$, or by Hal, NO_2 , CN, OR, A, $-(CY_2)_n$ -OR, -OCOR, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$ or $-(CY_2)_n-NR_2$,


R^7 denotes $(C=O)-R$, $(C=O)-NR_2$, $(C=O)-OR$, H or A

and

n, m, independently of one another, denote 0, 1, 2, 3, 4, 5, 6 or 7

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

In an embodiment, there is provided a compound of formula I



in which

W is CH or N;

R^1 is H, A, $(CY_2)_n-SA$, $-(CY_2)_n-SCF_3$, $-(CY_2)_n-SCN$, $-(CY_2)_n-CF_3$, $-(CY_2)_n-OCF_3$, cycloalkyl, $-(CY_2)_n-OH$, $(CY_2)_n-CN$, $-(CY_2)_n-Hal$, $(CY_2)_n-OA$, or $-(CY_2)_n-NHCOA$;

R^2 and R^3 , independently of one another, are each H, A, aryl, heteroaryl, Hal, $-(CY_2)_n-SA$, $-(CY_2)_n-SCF_3$, $-(CY_2)_n-SCN$, $-(CY_2)_n-CF_3$, $-(CY_2)_n-OCF_3$, cycloalkyl, $-SCH_3$, $-SCN$, $-CF_3$, $-OCF_3$, $-OA$, $-(CY_2)_n-OH$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$,

26474-1066

- 9a -

$-(CY_2)_n-Hal$, $-(CY_2)_n-NR_2$, $(CY_2)_n-OA$, $(CY_2)_n-OCOA$, $-SCF_3$, $(CY_2)_n-CONR_2-(CY_2)_n-NHCOA$, or $-(CY_2)_n-NHSO_2A$;

Y is H, A, or Hal;

A is alkyl;

5 Hal is F, Cl, Br or I;

R is H or A, in the case of geminal radicals R together also $-(CH_2)_5-$ or $-(CH_2)_4-$;

R^4 and R^5 together are $-X(CH_2)_2X-$, $-XCH(CH_2OR)CR_2X-$, $-XCR_2CH(CH_2OR)X-$, $-XCH(CH_2NR_2)CR_2X-$ or $-XCR_2CH(CH_2NR_2)X-$;

10 X is O;

R^6 is aryl or heteroaryl, each of which is unsubstituted or mono- or polysubstituted by aryl or heteroaryl, each of which may be substituted by Hal, NO_2 , CN, A, OR, OCOR, NR_2 , CF_3 , OCF_3 or $OCH(CF_3)_2$, or by Hal, NO_2 , CN, OR, A, $-(CY_2)_n-OR$, $-OCOR$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$ or $-(CY_2)_n-NR_2$;

15 R^7 is $(C=O)-R$, $(C=O)-NR_2$, $(C=O)-OR$, H or A; and


n and m, independently of one another, are each 0, 1, 2, 3, 4, 5, 6 or 7,

or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios.

In another embodiment, there is provided a mixture comprising one or more
 20 compounds as described herein, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, and an amount of one or more compounds of formula VI:

26474-1066

- 9b -




in which

Y' and Z' each, independently of one another, are O or N,

R^{7'} and R^{9'} each, independently of one another, are H, OH, halogen,
 5 OC1-10-alkyl, OCF₃, NO₂ or NH₂,

p is an integer between 2 and 6, each inclusive, and

R^{6'} and R^{8'} are each, independently of one another, in the meta- or
 para-position and are selected from:



10

The invention also relates to the optically active forms (stereoisomers), the
 enantiomers, the racemates, the diastereomers and the hydrates and solvates of
 these compounds. The term solvates of the compounds is taken to mean adductions
 of inert solvent molecules onto the compounds which form owing to their mutual
 15 attractive force. Solvates are, for example, mono- or dihydrates or alkoxides.

The term pharmaceutically usable derivatives is taken to mean, for example, the salts
 of the compounds according to the invention and also so-called prodrug compounds.

26474-1066

- 9c -

The term prodrug derivatives is taken to mean compounds of the formula I which have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention.

These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995).

5 The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.

10 In addition, the expression "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequences:

15 improved healing treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side-effects or also the reduction in the progress of a disease, condition or disorder.


The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function.

20 The invention also relates to the use of mixtures of the compounds according to the invention, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.

These are particularly preferably mixtures of stereoisomeric compounds.


25 The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I according to the patent claims and pharmaceutically usable derivatives,
30 salts, solvates and stereoisomers thereof, characterised in that a compound of the formula II

35



in which R^1 , R^2 and R^3 have the meanings indicated above,

is reacted with a compound of the formula III




in which

R^6 has the meaning indicated above,

and

with a compound of the formula III, the double-bond isomer (E isomer) thereof or mixtures thereof



in which R^4 and R^5 have the meanings indicated above,

preferably in the presence of a protonic acid or Lewis acid, such as, for example, trifluoroacetic acid, hexafluoroisopropanol, bismuth(III) chloride, ytterbium(III) triflate, scandium(III) triflate or cerium(IV) ammonium nitrate,

and a radical other than H is optionally introduced by conventional methods for R^7 .

5 The mixtures of diastereomers and enantiomers of the compounds of the formula I which may be obtained by the process described above are preferably separated by chromatography or crystallisation. If W does not denote CH, corresponding compounds of the formula II are employed for the preparation process.

10 If desired, the bases and acids of the formula I obtained by the process described above are converted into their salts.

Above and below, the radicals W, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, X, Y and n have the meanings indicated for the formula I, unless expressly indicated otherwise. If individual radicals occur a number of times within a compound, the radicals adopt the meanings indicated, independently of one another.

20 A denotes alkyl, is preferably unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 25 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, 30 tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl. A also denotes cycloalkyl.

Cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

35 R¹ preferably denotes A, CF₃, OCF₃, SA, SCN, CH₂CN, -OCOA, Hal, SCF₃, preferably also t-butyl, -CH(CH₃)CH₂CH₃, isopropyl, ethyl or methyl.

In particular, R^1 denotes t-butyl, isopropyl, ethyl, CF_3 , methyl, Br, Cl, SCF_3 , $CH(CH_3)CH_2CH_3$, n-propyl, OCH_3 , SCH_3 , n-butyl, -SCN, CH_2CN . R^1 particularly preferably denotes t-butyl, isopropyl, ethyl or CF_3 .


5 R^2 preferably denotes Hal, A or OA, in particular Br, cyclopropyl, OCH_3 . Particular preference is furthermore given to H or F.

10 R^3 preferably denotes H or A, in particular H. R^3 is preferably in the 5-position. In particular, R^3 denotes H or F.


In particularly preferred compounds of the formula I, R^2 and R^3 simultaneously have the meaning H. In further preferred compounds of the formula I, one of the radicals R^2 and R^3 has the meaning H and the other radical has the meaning F.

R^5 together with R^4 preferably adopts one of the following meanings:

20



25




30

in which X and R have the above-mentioned meaning and X denotes, in particular, O.


R^4 together with R^5 particularly preferably adopts one of the following meanings:

35




in which R has the above-mentioned meaning.

15 R^6 preferably denotes phenyl, 2-, 3- or 4-pyridyl, pyrimidyl, furyl or thienyl, each of which is unsubstituted or mono- or polysubstituted by Hal, CN, NO_2 , OH, CF_3 , $OCH(CF_3)_2$, $OCOCH_3$ or A. In particular, R^6 denotes one of the following groups:




35




10 in which

Q denotes O or S, A has the meaning indicated above, but preferably denotes methyl, and Hal preferably denotes F or Cl.

15 Particular preference is furthermore given to compounds of the formula I in which R⁶ has one of the following meanings:





10

R^7 preferably denotes H or A, in particular H.

15

Aryl preferably denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2 , NO_2 , CN, COOH, COOA, $CONH_2$, $NHCOA$, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 , SO_2A , $-CH_2-COOH$ or $-OCH_2-COOH$.

20

Aryl preferably denotes phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methylaminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N,N-diethylamino)phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-(methylsulfonamido)phenyl, o-, m- or p-(methylsulfonyl)phenyl, furthermore preferably

2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-,

35

2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-
3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-
chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-
bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acet-
amidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-
chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

Heteroaryl preferably denotes a mono- or bicyclic aromatic heterocycle
having one or more N, O and/or S atoms which is unsubstituted or mono-,
di- or trisubstituted by Hal, A, NO₂, NHA, NA₂, OA, COOA or CN.

Heteroaryl particularly preferably denotes a monocyclic saturated or aro-
matic heterocycle having one N, S or O atom, which may be unsubstituted
or mono-, di- or trisubstituted by Hal, A, NHA, NA₂, NO₂, COOA or benzyl.

Irrespective of further substitutions, unsubstituted heteroaryl denotes, for
example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imid-
azolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl,
2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or
6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-tri-
azol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-
oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl,
1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6-
or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-,
6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-
benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benziso-
thiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-
quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl,
2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxaliny, 2-, 3-, 5-, 6-, 7- or
8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-
benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-
5-yl.


Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl.

5

Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another.

Compounds of the formula A:

10



15

in which

R¹, R², R³, independently of one another, denote H, A, aryl, hetero-
 aryl, Hal, -(CY₂)_n-SA, -(CY₂)_n-SCF₃, -(CY₂)_n-SCN, -
 (CY₂)_n-CF₃, -(CY₂)_n-OCF₃, cycloalkyl, -SCH₃, -SCN,
 -CF₃, -OCF₃, -OA, -(CY₂)_n-OH, -(CY₂)_n-CO₂R,
 -(CY₂)_n-CN, -(CY₂)_n-Hal, -(CY₂)_n-NR₂, (CY₂)_n-OA,
 (CY₂)_n-OCOA, -SCF₃, (CY₂)_n-CONR₂, -(CY₂)_n-NHCOA,
 -(CY₂)_n-NHSO₂A

25

Y denotes H, A, Hal

30

A denotes alkyl or cycloalkyl

Hal denotes , Cl, Br or I

35

R denotes H or A, in the case of geminal radicals R together also -(CH₂)₅-, -(CH₂)₄- or -(CH₂)₂-NR-(CH₂)₂,

R^4, R^5 together denote $-X (CH_2)_2X-$, $-X CR_2)X-$,
 $-X CH(CH_2OR)X-$, $-X CH(CH_2OR)CR_2X-$,
 $-X CR_2CH(CH_2OR) X-$, $-X CH(CH_2NR_2)X-$,
 $-X CH(CH_2NR_2)CR_2X-$, $-X CR_2CH(CH_2NR_2) X-$,
 $-OCH_2CH_2O-$, $-X (CH_2)_2X-$,
 $-X CR_2)X-$, $-X CH(CH_2OR)X-$, $-X CH(CH_2OR)CR_2X-$,
 $-X CH(CH_2NR_2)X-$, $-X CH(CH_2NR_2)CR_2X-$, $-OCH_2CH_2O-$, $-X-\overset{\overset{||}{X}}{C}-X-$,

X denotes O, S or NR

R^6 denotes aryl or heteroaryl, each of which is unsubstituted or mono- or polysubstituted by aryl or heteroaryl, each of which may be substituted by Hal, NO_2 , CN, A, OR, OCOR, NR_2 , CF_3 , OCF_3 , $OCH(CF_3)_2$, or by Hal, NO_2 , CN, OR, A, $-(CY_2)_n-OR$, $-OCOR$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$ or $-(CY_2)_n-NR_2$,

R^7 denotes $(C=O)-R$, $(C=O)-NR_2$, $(C=O)-OR$, H or A

and



n denotes 0, 1, 2, 3, 4, 5, 6 or 7

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

W preferably denotes CH.

The compounds of the formula I may have one or more chiral centres and therefore exist in various stereoisomeric forms. The formula I encompasses all these forms.

5 Particularly preferred compounds of the formula I are those of the subformulae IA to IB:







25 in which
R, R¹, R², R⁶, R⁷ and X have the meanings indicated above

and

30 R⁸ denotes H, CH₂OR or CH₂NR₂.

Particularly preferred compounds of the formula IA are those of the subformulae IA1 to IA3:

35



in which R, R¹, R², R³, R⁶ and R⁷ have the meanings indicated above.


30 In particularly preferred compounds of the formula IB, R⁸ has the meaning H.

35 The radicals R⁴ and R⁵ are particularly preferably in the cis-position to one another. The radical R⁶ is furthermore preferably in the trans-position to the radical R⁵.

Preference is given here to a compound of the formula A or B having the following structure:

5

10




and the racemate thereof or other mixtures of the enantiomers.

15

Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae I1 to I43:


20

I1



25

I1a




35

26474-1066


- 23 -

12



5


12a



10


15

13



20


13a



25

30





14



35

26474-1066

- 24 -








18

35




26474-1066

- 25 -



26474-1066

- 26 -



20





25

30

35

26474-1066

- 27 -




35

26474-1066

- 28 -


5

I15



10


I16



15


20

I16a



25


I17



30


5

I18



10


I18a



15


20

I19



25

I19a




30

35


26474-1066

- 30 -


I20




I21




I21a




I22




I23




I24



I24a



I25




26474-1066

- 32 -


5

I26



10


I27



15

20


I27a



25

30

I28




35


26474-1066

- 33 -

5




10




15

20




25



30


5

I30a




10

I31



15


I31a



20


25

I32




30

35




5

I34a



10


I35



15

20


I35a



25

30

I36




35


26474-1066

- 37 -


5



10




15



20


25



30


5

I39



10

I40




15

20


25

I40a



30

35



5 The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use may also be made here of variants known per se which are not mentioned here
10 in greater detail.

15 If desired, the starting materials may also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula I.

20 The reaction is generally carried out in an inert solvent, preferably in the presence of a protonic acid or Lewis acid, such as TFA, HFIP, bismuth(III) salts, ytterbium(III) salts or CAN. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0° and 180°, normally between 0° and 100°, particularly preferably between 15° and 35°C.

25 Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; nitriles, such as acetonitrile; carbon disulfide;
30 carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene, or mixtures of the said solvents.

35 Compounds of the formula I in which R⁷ has a meaning other than H are preferably prepared by alkylation or acylation from the compounds of the formula I in which R⁷ denotes H.

5 If desired, a functionally modified amino and/or hydroxyl group in a compound of the formula I can be liberated by solvolysis or hydrogenolysis by conventional methods. This can be carried out, for example, using NaOH or KOH in water, water/THF or water/dioxane at temperatures between 0 and 100°.

10 The reduction of an ester to the aldehyde or alcohol or the reduction of a nitrile to the aldehyde or amine is carried out by methods as are known to the person skilled in the art and are described in standard works of organic chemistry.

15 The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium
20 hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of the compounds of the formula I are likewise included. In the case of certain compounds of the formula I, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen
25 halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such
30
35

as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentane-propionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction.

Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chlorprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-

5 ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethyl-piperidine, glucamine, glucosamine, histidine, hydrabamine, isopropyl-amine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction.

10 Compounds of the present invention which contain basic nitrogen-contain-
ing groups can be quaternised using agents such as (C₁-C₄)alkyl halides,
for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and
iodide; di(C₁-C₄)alkyl sulfates, for example dimethyl, diethyl and diamyl
15 sulfate; (C₁₀-C₁₈)alkyl halides, for example decyl, dodecyl, lauryl, myristyl
and stearyl chloride, bromide and iodide; and aryl(C₁-C₄)alkyl halides, for
example benzyl chloride and phenethyl bromide. Both water- and oil-solu-
ble compounds according to the invention can be prepared using such
salts.

20 The above-mentioned pharmaceutical salts which are preferred include
acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisucci-
nate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, me-
25 glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-
rate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and trometh-
amine, but this is not intended to represent a restriction.

30 The acid-addition salts of basic compounds of the formula I are prepared
by bringing the free base form into contact with a sufficient amount of the
desired acid, causing the formation of the salt in a conventional manner.
The free base can be regenerated by bringing the salt form into contact
35 with a base and isolating the free base in a conventional manner. The free
base forms differ in a certain respect from the corresponding salt forms
thereof with respect to certain physical properties, such as solubility in

polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

5 As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, di-
10 ethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient
15 amount of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solu-
20 bility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

If a compound according to the invention contains more than one group
25 which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.
30

With regard to that stated above, it can be seen that the term "pharmaceutically acceptable salt" in the present connection is taken to mean an
35 active ingredient which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form

of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.

The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.

Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes

known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).

5 Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

10 Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

20 Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medicament after the capsule has been taken.

30 In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and

synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acacia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.

The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be

5 coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyranes, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.

10 Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).

15 Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

20 For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with
25 an oil-in-water cream base or a water-in-oil base.

30 Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.

35 Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

5 Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.

15 Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.

20 Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

25 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.

35 Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.

5 It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.

10 A therapeutically effective amount of a compound of the formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an
15 effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to
20 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt
25 or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention *per se*. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

30 The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
35

The invention also relates to a set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

5 and

(b) an effective amount of a further medicament active ingredient.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each containing an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

10 and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.

The medicaments from Table 1 are preferably, but not exclusively, combined with the compounds of the formula I. A combination of the formula I and medicaments from Table 1 can also be combined with compounds of the formula VI.

15 20

25

30	Alkylating agents	Cyclophosphamide Busulfan Ifosfamide Melphalan Hexamethylmelamine Thiotepa Chloroambucil Dacarbazine Carmustine	Lomustine Procarbazine Altretamine Estramustine phosphate Mechloroethamine Streptozocin Temozolomide Semustine
	Platinum agents	Cisplatin Oxaliplatin Spiroplatin Carboxyphthalatoplatinum Tetraplatin Ormiplatin	Carboplatin ZD-0473 (AnorMED) Lobaplatin (Aetema) Satraplatin (Johnson Matthey) BBR-3464

35

	Iproplatin	(Hoffmann-La Roche) SM-11355 (Sumitomo) AP-5280 (Access)
5	Antimetabolites	Azacytidine Gemcitabine Capecitabine 5-Fluorouracil Floxuridine 2-Chlorodesoxyadenosine 6-Mercaptopurine 6-Thioguanine Cytarabine 2-Fluordesoxycytidine Methotrexate Idatrexate
10		Tomudex Trimetrexate Deoxycoformycin Fludarabine Pentostatin Raltitrexed Hydroxyurea Decitabine (SuperGen) Clofarabine (Bioenvision) Irofulven (MGI Pharma) DMDC (Hoffmann-La Roche) Ethynylcytidine (Taiho)
15	Topoisomerase inhibitors	Amsacrine Epirubicin Etoposide Teniposide or mitoxantrone Irinotecan (CPT-11) 7-Ethyl-10-hydroxycamptothecin Topotecan Dexrazoxane (TopoTarget) Pixantrone (Novuspharma) Rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharma)
20		Rubitecan (SuperGen) Exatecan mesylate (Daiichi) Quinamed (ChemGenex) Gimatecan (Sigma-Tau) Diflomotecan (Beaufour-Ipsen) TAS-103 (Taiho) Elsamitrucin (Spectrum) J-107088 (Merck & Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun Dang) KW-2170 (Kyowa Hakko)
25		
30	Antitumour antibiotics	Dactinomycin (Actinomycin D) Doxorubicin (Adriamycin) Deoxyrubicin Valrubicin Daunorubicin (Daunomycin) Epirubicin Thiarubicin Idarubicin Rubidazone Plicamycin Porfirimycin
35		Amonafide Azonafide Anthrapyrazole Oxantrazole Losoxantrone Bleomycin sulfate (Blenoxan) Bleomycinic acid Bleomycin A Bleomycin B Mitomycin C MEN-10755 (Menarini) GPX-100 (Gem)

	Cyanomorpholinodoxo- rubicin Mitoxantron (Novantron)	Pharmaceuticals)
5	Antimitotic agents	Paclitaxel Docetaxel Colchicine Vinblastine Vincristine Vinorelbine Vindesine Dolastatin 10 (NCI) Rhizoxin (Fujisawa) Mivobulin (Warner- Lambert) Cemadotin (BASF) RPR 109881A (Aventis) TXD 258 (Aventis) Epothilone B (Novartis) T 900607 (Tularik) T 138067 (Tularik) Cryptophycin 52 (Eli Lilly) Vinflunine (Fabre) Auristatin PE (Teikoku Hormone) BMS 247550 (BMS) BMS 184476 (BMS) BMS 188797 (BMS) Taxoprexin (Protarga)
10		SB 408075 (GlaxoSmithKline) E7010 (Abbott) PG-TXL (Cell Therapeutics) IDN 5109 (Bayer) A 105972 (Abbott) A 204197 (Abbott) LU 223651 (BASF) D 24851 (ASTA Medica) ER-86526 (Eisai) Combretastatin A4 (BMS) Isohomohalichondrin-B (PharmaMar) ZD 6126 (AstraZeneca) PEG-Paclitaxel (Enzon) AZ10992 (Asahi) IDN-5109 (Indena) AVLB (Prescient NeuroPharma) Azaepothilon B (BMS) BNP- 7787 (BioNumerik) CA-4-Prodrug (OXiGENE) Dolastatin-10 (NrH) CA-4 (OXiGENE)
15		
20		
25	Aromatase inhibitors	Aminoglutethimide Letrozole Anastrozole Formestan Exemestan Atamestan (BioMedicines) YM-511 (Yamanouchi)
30	Thymidylate synthase inhibitors	Pemetrexed (Eli Lilly) ZD-9331 (BTG) Nolatrexed (Eximias) CoFactor™ (BioKeys)
35	DNA antagonists	Trabectedin (PharmaMar) Glufosfamide (Baxter International) Albumin + 32P (Isotope Solutions) Thymectacin (NewBiotics) Edotreotid (Novartis) Mafosfamide (Baxter International) Apaziquone (Spectrum Pharmaceuticals) O6-Benzylguanine (Paligent)

5	Farnesyl transferase inhibitors	Arglabin (NuOncology Labs) lonafarnib (Schering-Plough) BAY-43-9006 (Bayer)	Tipifarnib (Johnson & Johnson) Perillyl alcohol (DOR BioPharma)
	Pump inhibitors	CBT-1 (CBA Pharma) Tariquidar (Xenova) MS-209 (Schering AG)	Zosuquidar trihydrochloride (Eli Lilly) Biricodar dicitrate (Vertex)
	Histone acetyl transferase inhibitors	Tacedinaline (Pfizer) SAHA (Aton Pharma) MS-275 (Schering AG)	Pivaloyloxymethyl butyrate (Titan) Depsipeptide (Fujisawa)
15	Metalloproteinase inhibitors	Neovastat (Aeterna Laboratories)	CMT -3 (CollaGenex)
	Ribonucleoside reductase inhibitors	Marimastat (British Biotech) Gallium maltolate (Titan) Triapin (Vion)	BMS-275291 (Celltech) Tezacitabine (Aventis) Didox (Molecules for Health)
	TNF-alpha agonists/ antagonists	Virulizin (Lorus Therapeutics) CDC-394 (Celgene)	Revimid (Celgene)
20	Endothelin-A receptor antagonists	Atrasentan (Abbot) ZD-4054 (AstraZeneca)	YM-598 (Yamanouchi)
	Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson) LGD-1550 (Ligand)	Alitretinoin (Ligand)
	Immuno-modulators	Interferon Oncophage (Antigenics) GMK (Progenics) Adenocarcinoma vaccine (Biomira) CTP-37 (AVI BioPharma) JRX-2 (Immuno-Rx) PEP-005 (Peplin Biotech) Synchrovax vaccines (CTL Immuno) Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVax)	Dexosome therapy (Anosys) Pentrix (Australian Cancer Technology) JSF-154 (Tragen) Cancer vaccine (Intercell) Norelin (Biostar) BLP-25 (Biomira) MGV (Progenics) !3-Alethin (Dovetail) CLL-Thera (Vasogen)
30			
35			

5	Hormonal and antihormonal agents	Oestrogens Conjugated oestrogens Ethinylloestradiol Chlorotrianisene Idenestrol Hydroxyprogesterone caproate Medroxyprogesterone Testosterone Testosterone propionate Fluoxymesterone Methyltestosterone Diethylstilbestrol Megestrol Tamoxifen Toremofin Dexamethasone	Prednisone Methylprednisolone Prednisolone Aminoglutethimide Leuprolide Goserelin Leuporelin Bicalutamide Flutamide Octreotide Nilutamide Mitotan P-04 (Novogen) 2-Methoxyoestradiol (EntreMed) Arzoxifen (Eli Lilly)
15	Photodynamic agents	Talaporfin (Light Sciences) Theralux (Theratechnologies) Motexafin-Gadolinium (Pharmacyclics)	Pd-Bacteriopheophorbid (Yeda) Lutetium-Texaphyrin (Pharmacyclics) Hypericin
20	Tyrosine kinase inhibitors	Imatinib (Novartis) Leflunomide(Sugen/Pharmacia) ZD1839 (AstraZeneca) Erlotinib (Oncogene Science) Canertinib (Pfizer) Squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia) ZD4190 (AstraZeneca) ZD6474 (AstraZeneca) Vatalanib (Novartis) PKI166 (Novartis) GW2016 (GlaxoSmithKline) EKB-509 (Wyeth) EKB-569 (Wyeth)	Kahalide F (PharmaMar) CEP- 701 (Cephalon) CEP-751 (Cephalon) MLN518 (Millenium) PKC412 (Novartis) Phenoxodiol O Trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech) MDX-H210 (Medarex) 2C4 (Genentech) MDX-447 (Medarex) ABX-EGF (Abgenix) IMC-1C11 (ImClone)
35	Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP	BCX-1777 (PNP inhibitor, BioCryst) Ranpirnase (ribonuclease stimulant, Alfacell)

	agonist, Ribapharm)	Galarubicin (RNA
	Alvocidib (CDK inhibitor,	synthesis inhibitor, Dong-
	Aventis)	A)
	CV-247 (COX-2 inhibitor,	Tirapazamine (reducing
	Ivy Medical)	agent, SRI International)
5	P54 (COX-2 inhibitor,	N-Acetylcysteine (reducing
	Phytopharm)	agent, Zambon)
	CapCell™ (CYP450	R-Flurbiprofen (NF-kappaB
	stimulant, Bavarian Nordic)	inhibitor, Encore)
	GCS-100 (gal3 antagonist,	3CPA (NF-kappaB
	GlycoGenesys)	inhibitor, Active Biotech)
10	G17DT immunogen	Seocalcitol (vitamin D
	(gastrin inhibitor, Aphton)	receptor agonist, Leo)
	Efaproxiral (oxygenator,	131-I-TM-601 (DNA
	Allos Therapeutics)	antagonist,
	PI-88 (heparanase	TransMolecular)
	inhibitor, Progen)	Eflornithin (ODC inhibitor,
	Tesmilifen (histamine	ILEX Oncology)
15	antagonist, YM	Minodronic acid
	BioSciences)	(osteoclast inhibitor,
	Histamine (histamine H2	Yamanouchi)
	receptor agonist, Maxim)	Indisulam (p53 stimulant,
	Tiazofurin (IMPDH	Eisai)
	inhibitor, Ribapharm)	Aplidin (PPT inhibitor,
	Cilengitide (integrin	PharmaMar)
20	antagonist, Merck KGaA)	Rituximab (CD20 antibody,
	SR-31747 (IL-1 antagonist,	Genentech)
	Sanofi-Synthelabo)	Gemtuzumab (CD33
	CCI-779 (mTOR kinase	antibody, Wyeth Ayerst)
	inhibitor, Wyeth)	PG2 (haematopoiesis
	Exisulind (PDE-V inhibitor,	promoter, Pharmagenesis)
25	Cell Pathways)	Immunol™ (triclosan
	CP-461 (PDE-V inhibitor,	mouthwash, Endo)
	Cell Pathways)	Triacetyluridine (uridine
	AG-2037 (GART inhibitor,	prodrug, Wellstat)
	Pfizer)	SN-4071 (sarcoma agent,
	WX-UK1 (plasminogen	Signature BioScience)
	activator inhibitor, Willex)	TransMID-107™
30	PBI-1402 (PMN stimulant,	(immunotoxin, KS
	ProMetic LifeSciences)	Biomedix)
	Bortezomib (proteasome	PCK-3145 (apoptosis
	inhibitor, Millennium)	promoter, Procyon)
	SRL-172 (T-cell stimulant,	Doranidazole (apoptosis
	SR Pharma)	promoter, Pola)
35	TLK-286 (glutathione-S	CHS-828 (cytotoxic agent,
	transferase inhibitor, Telik)	Leo)
	PT-100 (growth factor	Trans-retinic acid

5		agonist, Point Therapeutics) Midostaurin (PKC inhibitor, Novartis) Bryostatin-1 (PKC stimulant, GPC Biotech) CDA-II (apoptosis promoter, Everlife) SDX-101 (apoptosis promoter, Salmedix) Ceflatonin (apoptosis promoter, ChemGenex)	(differentiator, NIH) MX6 (apoptosis promoter, MAXIA) Apomine (apoptosis promoter, ILEX Oncology) Urocidin (apoptosis promoter, Bioniche) Ro-31-7453 (apoptosis promoter, La Roche) Brostallicin (apoptosis promoter, Pharmacia)
10			
15	Alkylating agents	Cyclophosphamide Busulfan Ifosfamide Melphalan Hexamethylmelamine Thiotepa Chloroambucil Dacarbazine Carmustine	Lomustine Procarbazine Altretamine Estramustine phosphate Mechloroethamine Streptozocin Temozolomide Semustine
20			
25	Platinum agents	Cisplatin Oxaliplatin Spiroplatin Carboxyphthalatoplatinum Tetraplatin Ormiplatin Iproplatin	Carboplatin ZD-0473 (AnorMED) Lobaplatin (Aetema) Satraplatin (Johnson Matthey) BBR-3464 (Hoffmann-La Roche) SM-11355 (Sumitomo) AP-5280 (Access)
30			
35	Antimetabolites	Azacytidine Gemcitabine Capecitabine 5-Fluorouracil Floxuridine 2-Chlorodesoxyadenosine 6-Mercaptopurine 6-Thioguanine Cytarabine 2-Fluordesoxycytidine Methotrexate Idatrexate	Tomudex Trimetrexate Deoxycoformycin Fludarabine Pentostatin Raltitrexed Hydroxyurea Decitabine (SuperGen) Clofarabine (Bioenvision) Irofulven (MGI Pharrna) DMDC (Hoffmann-La Roche) Ethinylcytidine (Taiho)

5	Topoisomerase inhibitors	Amsacrine Epirubicin Etoposide Teniposide or mitoxantrone Irinotecan (CPT-11) 7-Ethyl-10-hydroxycamptothecin Topotecan Dexrazoxanet (TopoTarget) Pixantrone (Novuspharma) Rebeccamycin analogue (Exelixis) BBR-3576 (Novuspharma)	Rubitecan (SuperGen) Exatecan mesylate (Daiichi) Quinamed (ChemGenex) Gimatecan (Sigma- Tau) Diflomotecan (Beaufour-Ipsen) TAS-103 (Taiho) Elsamitrucin (Spectrum) J-107088 (Merck & Co) BNP-1350 (BioNumerik) CKD-602 (Chong Kun Dang) KW-2170 (Kyowa Hakko)
15	Antitumour antibiotics	Dactinomycin (Actinomycin D) Doxorubicin (Adriamycin) Deoxyrubicin Valrubicin Daunorubicin (Daunomycin) Epirubicin Therarubicin Idarubicin Rubidazon Plicamycin Porfiromycin Cyanomorpholinodoxo-rubicin Mitoxantron (Novantron)	Amonafide Azonafide Anthrapyrazole Oxantrazole Losoantrone Bleomycin sulfate (Blenoxan) Bleomycinic acid Bleomycin A Bleomycin B Mitomycin C MEN-10755 (Menarini) GPX-100 (Gem Pharmaceuticals)
30	Antimitotic agents	Paclitaxel Docetaxel Colchicine Vinblastine Vincristine Vinorelbine Vindesine Dolastatin 10 (NCI) Rhizoxin (Fujisawa) Mivobulin (Warner-Lambert) Cemadotin (BASF) RPR 109881A (Aventis) TXD 258 (Aventis)	SB 408075 (GlaxoSmithKline) E7010 (Abbott) PG-TXL (Cell Therapeutics) IDN 5109 (Bayer) A 105972 (Abbott) A 204197 (Abbott) LU 223651 (BASF) D 24851 (ASTA Medica) ER-86526 (Eisai) Combretastatin A4 (BMS) Isohomohalichondrin-B (PharmaMar)

5		Epothilone B (Novartis) T 900607 (Tularik) T 138067 (Tularik) Cryptophycin 52 (Eli Lilly) Vinflunine (Fabre) Auristatin PE (Teikoku Hormone) BMS 247550 (BMS) BMS 184476 (BMS) BMS 188797 (BMS) Taxoprexin (Protarga)	ZD 6126 (AstraZeneca) PEG-Paclitaxel (Enzon) AZ10992 (Asahi) !DN-5109 (Indena) AVLB (Prescient NeuroPharma) Azaepothilon B (BMS) BNP- 7787 (BioNumerik) CA-4-Prodrug (OXiGENE) Dolastatin-10 (NrH) CA-4 (OXiGENE)
10	Aromatase inhibitors	Aminoglutethimide Letrozole Anastrozole Formestan	Exemestan Atamestan (BioMedicines) YM-511 (Yamanouchi)
15	Thymidylate synthase inhibitors	Pemetrexed (Eli Lilly) ZD-9331 (BTG)	Nolatrexed (Eximias) CoFactor™ (BioKeys)
20	DNA antagonists	Trabectedin (PharmaMar) Glufosfamide (Baxter International) Albumin + 32P (Isotope Solutions) Thymectacin (NewBiotics) Edotreotid (Novartis)	Mafosfamide (Baxter International) Apaziquone (Spectrum Pharmaceuticals) O6-Benzylguanine (Paligent)
25	Farnesyl transferase inhibitors	Arglabin (NuOncology Labs) lonafarnib (Schering-Plough) BAY-43-9006 (Bayer)	Tipifarnib (Johnson & Johnson) Perillyl alcohol (DOR BioPharma)
30	Pump inhibitors	CBT-1 (CBA Pharma) Tariquidar (Xenova) MS-209 (Schering AG)	Zosuquidar trihydrochloride (Eli Lilly) Biricodar dicitrate (Vertex)
	Histone acetyl transferase inhibitors	Tacedinaline (Pfizer) SAHA (Aton Pharma) MS-275 (Schering AG)	Pivaloyloxymethyl butyrate (Titan) Depsipeptide (Fujisawa)
35	Metalloproteinase inhibitors Ribonucleoside reductase	Neovastat (Aeterna Laboratories) Marimastat (British Biotech)	CMT -3 (CollaGenex) BMS-275291 (Celltech) Tezacitabine (Aventis) Didox (Molecules for

5	inhibitors	Gallium maltolate (Titan Health) Triapin (Vion)
	TNF-alpha agonists/ antagonists	Virulizin (Lorus Therapeutics) Revimid (Celgene) CDC-394 (Celgene)
	Endothelin-A receptor antagonists	Atrasentan (Abbot) YM-598 (Yamanouchi) ZD-4054 (AstraZeneca)
10		
	Retinoic acid receptor agonists	Fenretinide (Johnson & Johnson) Alitretinoin (Ligand) LGD-1550 (Ligand)
15	Immuno-modulators	Interferon
		Oncophage (Antigenics)
		GMK (Progenics)
		Adenocarcinoma vaccine (Biomira)
		CTP-37 (AVI BioPharma)
20		JRX-2 (Immuno-Rx)
		PEP-005 (Peplin Biotech)
		Synchrovax vaccines (CTL Immuno)
		Melanoma vaccine (CTL Immuno)
		p21-RAS vaccine (GemVax)
25	Hormonal and antihormonal agents	Dexosome therapy (Anosys)
		Pentrix (Australian Cancer Technology)
		JSF-154 (Tragen)
		Cancer vaccine (Intercell)
		Norelin (Biostar)
30		BLP-25 (Biomira)
		MGV (Progenics)
		I3-Alethin (Dovetail)
		CLL-Thera (Vasogen)
35		Oestrogens
		Conjugated oestrogens
		Ethinylloestradiol
		Chlorotrianisene
		Idenestrol
		Hydroxyprogesterone caproate
		Goserelin
		Leuporelin
		Bicalutamide
		Flutamide
		Octreotide
		Nilutamide
		Mitotan
		P-04 (Novogen)
		2-Methoxyoestradiol (EntreMed)
		Arzoxifen (Eli Lilly)
		Tamoxifen
		Toremofin
		Dexamethasone

5	Photodynamic agents	Talaporfin (Light Sciences) Theralux (Theratechnologies) Motexafin-Gadolinium (Pharmacyclics)	Pd-Bacteriopheophorbid (Yeda) Lutetium-Texaphyrin (Pharmacyclics) Hypericin
	Tyrosine kinase inhibitors	Imatinib (Novartis) Leflunomide(Sugen/Pharmacia) ZD1839 (AstraZeneca) Erlotinib (Oncogene Science) Canertjinib (Pfizer) Squalamine (Genaera) SU5416 (Pharmacia) SU6668 (Pharmacia) ZD4190 (AstraZeneca) ZD6474 (AstraZeneca) Vatalanib (Novartis) PKI166 (Novartis) GW2016 (GlaxoSmithKline) EKB-509 (Wyeth) EKB-569 (Wyeth)	Kahalide F (PharmaMar) CEP- 701 (Cephalon) CEP-751 (Cephalon) MLN518 (Millenium) PKC412 (Novartis) Phenoxodiol O Trastuzumab (Genentech) C225 (ImClone) rhu-Mab (Genentech) MDX-H210 (Medarex) 2C4 (Genentech) MDX-447 (Medarex) ABX-EGF (Abgenix) IMC-1C11 (ImClone)
10	Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP agonist, Ribapharm) Alvocidib (CDK inhibitor, Aventis) CV-247 (COX-2 inhibitor, Ivy Medical) P54 (COX-2 inhibitor, Phytopharm) CapCell™ (CYP450 stimulant, Bavarian Nordic) GCS-IOO (gal3 antagonist, GlycoGenesys) G17DT immunogen (gastrin inhibitor, Aphton) Efaproxiral (oxygenator, Allos Therapeutics) PI-88 (heparanase inhibitor, Progen) Tesmifen (histamine	BCX-1777 (PNP inhibitor, BioCryst) Ranpirnase (ribonuclease stimulant, Alfacell) Galarubicin (RNA synthesis inhibitor, Dong-A) Tirapazamine (reducing agent, SRI International) N-Acetylcysteine (reducing agent, Zambon) R-Flurbiprofen (NF-kappaB inhibitor, Encore) 3CPA (NF-kappaB inhibitor, Active Biotech) Seocalcitol (vitamin D receptor agonist, Leo) 131-I-TM-601 (DNA antagonist, TransMolecular) Eflornithin (ODC inhibitor, ILEX Oncology)
15			
20	Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP agonist, Ribapharm) Alvocidib (CDK inhibitor, Aventis) CV-247 (COX-2 inhibitor, Ivy Medical) P54 (COX-2 inhibitor, Phytopharm) CapCell™ (CYP450 stimulant, Bavarian Nordic) GCS-IOO (gal3 antagonist, GlycoGenesys) G17DT immunogen (gastrin inhibitor, Aphton) Efaproxiral (oxygenator, Allos Therapeutics) PI-88 (heparanase inhibitor, Progen) Tesmifen (histamine	BCX-1777 (PNP inhibitor, BioCryst) Ranpirnase (ribonuclease stimulant, Alfacell) Galarubicin (RNA synthesis inhibitor, Dong-A) Tirapazamine (reducing agent, SRI International) N-Acetylcysteine (reducing agent, Zambon) R-Flurbiprofen (NF-kappaB inhibitor, Encore) 3CPA (NF-kappaB inhibitor, Active Biotech) Seocalcitol (vitamin D receptor agonist, Leo) 131-I-TM-601 (DNA antagonist, TransMolecular) Eflornithin (ODC inhibitor, ILEX Oncology)
25			
30	Various agents	SR-27897 (CCK-A inhibitor, Sanofi-Synthelabo) Tocladesine (cyclic AMP agonist, Ribapharm) Alvocidib (CDK inhibitor, Aventis) CV-247 (COX-2 inhibitor, Ivy Medical) P54 (COX-2 inhibitor, Phytopharm) CapCell™ (CYP450 stimulant, Bavarian Nordic) GCS-IOO (gal3 antagonist, GlycoGenesys) G17DT immunogen (gastrin inhibitor, Aphton) Efaproxiral (oxygenator, Allos Therapeutics) PI-88 (heparanase inhibitor, Progen) Tesmifen (histamine	BCX-1777 (PNP inhibitor, BioCryst) Ranpirnase (ribonuclease stimulant, Alfacell) Galarubicin (RNA synthesis inhibitor, Dong-A) Tirapazamine (reducing agent, SRI International) N-Acetylcysteine (reducing agent, Zambon) R-Flurbiprofen (NF-kappaB inhibitor, Encore) 3CPA (NF-kappaB inhibitor, Active Biotech) Seocalcitol (vitamin D receptor agonist, Leo) 131-I-TM-601 (DNA antagonist, TransMolecular) Eflornithin (ODC inhibitor, ILEX Oncology)
35			

5	antagonist, YM BioSciences)	Minodronic acid (osteoclast inhibitor, Yamanouchi)
	Histamine (histamine H2 receptor agonist, Maxim)	Indisulam (p53 stimulant, Eisai)
	Tiazofurin (IMPDH inhibitor, Ribapharm)	Aplidin (PPT inhibitor, PharmaMar)
	Cilengitide (integrin antagonist, Merck KGaA)	Rituximab (CD20 antibody, Genentech)
	SR-31747 (IL-1 antagonist, Sanofi-Synthelabo)	Gemtuzumab (CD33 antibody, Wyeth Ayerst)
10	CCI-779 (mTOR kinase inhibitor, Wyeth)	PG2 (haematopoiesis promoter, Pharmagenesis)
	Exisulind (PDE-V inhibitor, Cell Pathways)	Immunol™ (triclosan mouthwash, Endo)
	CP-461 (PDE-V inhibitor, Cell Pathways)	Triacetyluridine (uridine prodrug, Wellstat)
	AG-2037 (GART inhibitor, Pfizer)	SN-4071 (sarcoma agent, Signature BioScience)
15	WX-UK1 (plasminogen activator inhibitor, Wilex)	TransMID-107™ (immunotoxin, KS Biomedix)
	PBI-1402 (PMN stimulant, ProMetic LifeSciences)	PCK-3145 (apoptosis promoter, Procyon)
	Bortezomib (proteasome inhibitor, Millennium)	Doranidazole (apoptosis promoter, Pola)
20	SRL-172 (T-cell stimulant, SR Pharma)	CHS-828 (cytotoxic agent, Leo)
	TLK-286 (glutathione-S transferase inhibitor, Telik)	Trans-retinic acid (differentiator, NIH)
	PT-100 (growth factor agonist, Point Therapeutics)	MX6 (apoptosis promoter, MAXIA)
25	Midostaurin (PKC inhibitor, Novartis)	Apomine (apoptosis promoter, ILEX Oncology)
	Bryostatin-1 (PKC stimulant, GPC Biotech)	Urocidin (apoptosis promoter, Bioniche)
	CDA-II (apoptosis promoter, Everlife)	Ro-31-7453 (apoptosis promoter, La Roche)
30	SDX-101 (apoptosis promoter, Salmedix)	Brostallicin (apoptosis promoter, Pharmacia)
	Ceflatonin (apoptosis promoter, ChemGenex)	

The compounds of the formula I are preferably combined with known anti-cancer agents:

5 The present compounds are also suitable for combination with known anti-cancer agents. These known anti-cancer agents include the following: oestrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors and other angiogenesis inhibitors. The present compounds are particularly suitable for administration at the same time as radiotherapy. The synergistic effects of inhibition of VEGF in combination with radiotherapy have been described by specialists (see WO 00/61186).

15 "Oestrogen receptor modulators" refers to compounds which interfere with or inhibit the binding of oestrogen to the receptor, regardless of mechanism. Examples of oestrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl)]phenyl 2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazine and SH646.

25 "Androgen receptor modulators" refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5 α -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate.

30 "Retinoid receptor modulators" refers to compounds which interfere with or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid, α -difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl)retinamide and N-4-carboxyphenylretinamide.

35

"Cytotoxic agents" refers to compounds which result in cell death primarily through direct action on the cellular function or inhibit or interfere with cell myosis, including alkylating agents, tumour necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors.

5 Examples of cytotoxic agents include, but are not limited to, tirapazimine, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, impro-
10 sulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-
aminedichloro(2-methylpyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)bis-mu-(hexane-1,6-diamine)mu-[diamine-
15 platinum(II)]bis[diamine(chloro)platinum(II)] tetrachloride, diarizidinyl-
spermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-
dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxan-
trone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplastone, 3'-de-
20 amino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin,
galarubicin, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-azirid-
inyl-4-methylsulfonyldaunorubicin (see WO 00/50032).

Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin,
25 dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-
methoxyphenyl)benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L-
valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and
30 BMS188797.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exobenzylidenechartre-
usin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-
35 (6H)propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-
methyl-1H,12H-benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-
10,13(9H,15H)dione, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)-

camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxyetoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a,5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one and dimesna.

"Antiproliferative agents" include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine, ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-mannoheptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b]-1,4-thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo-(7.4.1.0.0)tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabinofuranosyl cytosine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. "Antiproliferative agents" also include monoclonal antibodies to growth factors other than those listed under "angiogenesis inhibitors", such as trastuzumab, and tumour suppressor genes, such as

p53, which can be delivered via recombinant virus-mediated gene transfer (see US Patent No. 6,069,134, for example).

5 Particular preference is given to the use of the compound according to the invention for the treatment and prophylaxis of tumour diseases.

10 The tumour is preferably selected from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.

15 The tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.


20 Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

25 The invention also encompasses a method for the treatment of a patient who has a neoplasm, such as a cancer, by administration of


a) one or more of the compound of the formula I:

30


35



b) and one or more of the compounds of the formula VI:



15 in which Y' and Z' each, independently of one another, denote O or N, R^{7'} and R^{9'} each, independently of one another, denote H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂, p denotes an integer between 2 and 6, each inclusive, and R^{6'} and R^{8'} are each, independently of one another, preferably in the meta- or para-position and are selected from the group:



30 where the first and second compound are administered simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of the neoplasm.


35 The combination of the compounds of the formula I with the compounds of the formula VI and other pentamidine analogues results in a synergistic action in the inhibition of neoplasias.

The mechanism of action of pentamidine or derivatives thereof has not been clearly explained at present: pentamidine or derivatives thereof appears to have pleiotropic actions since it results in a decrease in DNA, RNA and protein synthesis. It was recently described that pentamidine is a capable inhibitor of PRL1, -2 and 3 phosphatases (Pathak et al., 2002) and tyrosine phosphatases, and overexpression thereof is accompanied by neoplastic malignant tumours in humans. On the other hand, it has been described that pentamidine is a medicament which binds to the DNA minor groove (Puckowska et al., 2004) and is able to exert its action via disturbance of gene expression and/or DNA synthesis.

Our attached experiments show that:

- both pentamidine and also the compounds of the formula I maintain cells in the G2/M cell cycle.
- the combination of pentamidine and compounds of the formula I have additive to synergistic actions on cell proliferation.



Other suitable pentamidine analogues include stilbamidine (G-1) and hydroxystilbamidine (G-2) and indole analogues thereof (for example G-3):



(G-1)

26474-1066

- 70 -



Each amidine unit may be replaced, independently of one another, by one of the units defined above for R⁸ and R⁹. As in the case of benzimidazoles and pentamidines, salts of stilbamidine, hydroxystilbamidine and indole derivatives thereof are also suitable in the process according to the invention. Preferred salts include, for example, dihydrochloride and methane-sulfonate salts.

Still other analogues are those which fall under a formula which are provided in one of the US Patents No. 5,428,051, 5,521,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 and 6,326,395 or the US patent application with the publication No. US 2002/0019437 A1.

Illustrative analogues include 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane, 1,3-bis(4'-(N-hydroxyamidino)phenoxy)propane, 1,3-bis(2'-methoxy-4'-(N-hydroxyamidino)phenoxy)propane, 1,4-bis(4'-(N-hydroxyamidino)phenoxy)butane, 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane, 1,4-bis(4'-(N-hydroxyamidino)phenoxy)butane, 1,3-bis(4'-(4-hydroxyamidino)phenoxy)propane, 1,3-bis(2'-methoxy-4'-(N-hydroxyamidino)phenoxy)propane, 2,5-bis[4-

amidinophenyl]furan, 2,5-bis[4-amidinophenyl]furan bisamide oxime, 2,5-bis[4-amidinophenyl]furan bis-O-methylamide oxime, 2,5-bis[4-amidinophenyl]furan bis-O-ethylamide oxime, 2,8-diamidinodibenzothiophene, 2,8-bis(N-isopropylamidino)carbazole, 2,8-bis(N-hydroxyamidino)carbazole, 2,8-bis(2-imidazoliny)l)dibenzothiophene, 2,8-bis(2-imidazoliny)l)-5,5-dioxodibenzothiophene, 3,7-diamidinodibenzothiophene, 3,7-bis(N-isopropylamidino)dibenzothiophene, 3,7-bis(N-hydroxyamidino)dibenzothiophene, 3,7-diaminodibenzothiophene, 3,7-dibromodibenzothiophene, 3,7-dicyanodibenzothiophene, 2,8-diamidinodibenzofuran, 2,8-di-(2-imidazoliny)l)dibenzofuran, 2,8-di-(N-isopropylamidino)dibenzofuran, 2,8-di-(N-hydroxylamidino)dibenzofuran, 3,7-di-(2-imidazoliny)l)dibenzofuran, 3,7-di-(isopropylamidino)dibenzofuran, 3,7-di-(A-hydroxylamidino)dibenzofuran, 2,8-dicyanodibenzofuran, 4,4'-dibromo-2,2'-dinitrobiphenyl, 2-methoxy-2'-nitro-4,4'-dibromobiphenyl, 2-methoxy-2'-amino-4,4'-dibromobiphenyl, 3,7-dibromodibenzofuran, 3,7-dicyanodibenzofuran, 2,5-bis(5-amidino-2-benzimidazolyl)pyrrole, 2,5-bis[5-(2-imidazoliny)l)-2-benzimidazolyl]pyrrole, 2,6-bis[5-(2-imidazoliny)l)-2-benzimidazolyl]pyridine, 1-methyl-2,5-bis(5-amidino-2-benzimidazolyl)pyrrole, 1-methyl-2,5-bis[5-(2-imidazolyl)-2-benzimidazolyl]pyrrole, 1-methyl-2,5-bis[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyrrole, 2,6-bis(5-amidino-2-benzimidazolyl)pyridine, 2,6-bis[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyridine, 2,5-bis(5-amidino-2-benzimidazolyl)furan, 2,5-bis[5-(2-imidazoliny)l)-2-benzimidazolyl]furan, 2,5-bis(5-N-isopropylamidino-2-benzimidazolyl)furan, 2,5-bis(4-guanylphenyl)furan, 2,5-bis(4-guanylphenyl)-3,4-dimethylfuran, 2,5-di-p-[2-(3,4,5,6-tetrahydropyrimidyl)phenyl]furan, 2,5-bis[4-(2-imidazoliny)l)-phenyl]furan, 2,5-[bis{4-(2-tetrahydropyrimidinyl)}phenyl]p-(tolyloxy)furan, 2,5-[bis{4-(2-imidazoliny)l)}phenyl]-3-p-(tolyloxy)furan, 2,5-bis{4-[5-(N-2-aminoethylamido)benzimidazol-2-yl]phenyl}furan, 2,5-bis[4-(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)phenyl]furan, 2,5-bis[4-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl)phenyl]furan, 2,5-bis(4-N,N-dimethylcarboxhydrazidophenyl)furan, 2,5-bis{4-[2-(N-2-hydroxyethyl)imidazoliny]l)-phenyl}furan, 2,5-bis[4-(N-isopropylamidino)phenyl]furan, 2,5-bis{4-[3-

(dimethylaminopropyl)amidino]phenyl}furan, 2,5-bis{4-[N-(3-aminopropyl)-amidino]phenyl}furan, 2,5-bis[2-(imidazolinyl)phenyl]-3,4-bis(methoxymethyl)furan, 2,5-bis[4-N-(dimethylaminoethyl)guanyl]phenylfuran, 2,5-bis{4-[(N-2-hydroxyethyl)guanyl]phenyl}furan, 2,5-bis[4-N-(cyclopropylguanyl)phenyl]furan, 2,5-bis[4-(N,N-diethylaminopropyl)guanyl]phenylfuran, 2,5-bis{4-[2-(N-ethylimidazolinyl)]phenyl}furan, 2,5-bis{4-[N-(3-pentylguanyl)]}phenylfuran, 2,5-bis[4-(2-imidazolinyl)phenyl]-3-methoxyfuran, 2,5-bis[4-(N-isopropylamidino)phenyl]-3-methylfuran, bis[5-amidino-2-benzimidazolyl]methane, bis[5-(2-imidazolyl)-2-benzimidazolyl]methane, 1,2-bis[5-amidino-2-benzimidazolyl]ethane, 1,2-bis[5-(2-imidazolyl)-2-benzimidazolyl]ethane, 1,3-bis[5-amidino-2-benzimidazolyl]propane, 1,3-bis[5-(2-imidazolyl)-2-benzimidazolyl]propane, 1,4-bis[5-amidino-2-benzimidazolyl]propane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]butane, 1,8-bis[5-amidino-2-benzimidazolyl]octane, trans-1,2-bis[5-amidino-2-benzimidazolyl]ethene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-methylbutane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2-ethylbutane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-methyl-1-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2,3-diethyl-2-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1,3-butadiene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2-methyl-1,3-butadiene, bis[5-(2-pyrimidyl)-2-benzimidazolyl]methane, 1,2-bis[5-(2-pyrimidyl)-2-benzimidazolyl]ethane, 1,3-bis[5-amidino-2-benzimidazolyl]propane, 1,3-bis[5-(2-pyrimidyl)-2-benzimidazolyl]propane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]butane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methylbutane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-ethylbutane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methyl-1-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2,3-diethyl-2-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1,3-butadiene and 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-methyl-1,3-butadiene, 2,4-bis(4-guanylphenyl)pyrimidine, 2,4-bis(4-imidazolin-2-yl)pyrimidine, 2,4-bis-

[(tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine, 2-(4-[N-i-propylguanyl]-phenyl)-4-(2-methoxy-4-[N-i-propylguanyl]phenyl)pyrimidine, 4-(N-cyclopentylamidino)-1,2-phenylenediamine, 2,5-bis[2-(5-amidino)benzimidazolyl]furan, 2,5-bis[2-{5-(2-imidazolino)}benzimidazolyl]furan, 2,5-bis[2-(5-N-isopropylamidino)benzimidazolyl]furan, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]furan, 2,5-bis[2-(5-amidino)benzimidazolyl]pyrrole, 2,5-bis[2-{5-(2-imidazolino)}benzimidazolyl]pyrrole, 2,5-bis[2-(5-N-isopropylamidino)benzimidazolyl]pyrrole, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]pyrrole, 1-methyl-2,5-bis[2-(5-amidino)benzimidazolyl]pyrrole, 2,5-bis[2-{5-(2-imidazolino)}benzimidazolyl]-1-methylpyrrole, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]-1-methylpyrrole, 2,5-bis[2-(5-N-isopropylamidino)benzimidazolyl]thiophene, 2,6-bis[2-{5-(2-imidazolino)}benzimidazolyl]pyridine, 2,6-bis[2-(5-amidino)benzimidazolyl]pyridine, 4,4'-bis[2-(5-N-isopropylamidino)benzimidazolyl]-1,2-diphenylethane, 4,4'-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]-2,5-diphenylfuran, 2,5-bis[2-(5-amidino)benzimidazolyl]benzo[b]furan, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazolyl]benzo[b]furan, 2,7-bis[2-(5-N-isopropylamidino)benzimidazolyl]fluorine, 2,5-bis[4-(3-(N-morpholinopropyl)carbamoyl)phenyl]furan, 2,5-bis[4-(2-N,N-dimethylaminoethylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N,N-dimethylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N-methyl-3-N-phenylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N,N8,N11-trimethylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[3-amidinophenyl]furan, 2,5-bis[3-(N-isopropylamidino)amidinophenyl]furan, 2,5-bis[3-[(N-(2-dimethylaminoethyl)amidino]phenyl]furan, 2,5-bis[4-(N-2,2,2-trichloroethoxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-thioethylcarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-benzyloxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-phenoxy-carbonyl)amidinophenyl]furan, 2,5-bis[4-(N-(4-fluoro)phenoxy-carbonyl)amidinophenyl]furan, 2,5-bis[4-(N-(4-methoxy)phenoxy-carbonyl)amidinophenyl]furan, 2,5-bis[4-(1-acetoxyethoxycarbonyl)amidinophenyl]furan and 2,5-bis[4-(N-(3-fluoro)phenoxy-carbonyl)amidinophenyl]furan. Processes for the preparation of one of the above compounds are described in US

patents No. 5,428,051, 5,521,189, 5,602,172, 5,643,935, 5,723,495, 5,843,980, 6,172,104 and 6,326,395 or the US patent application with the publication No. US 2002/0019437 A1.

5

10

Pentamidine metabolites are likewise suitable in the antiproliferative combination according to the invention. Pentamidine is rapidly metabolised in the body to at least seven primary metabolites. Some of these metabolites have one or more actions in common with pentamidine. Pentamidine metabolites have antiproliferative action when combined with a benzimidazole or an analogue thereof.

15


20

25

30

35

Seven pentamidine analogues are shown below.



25

The combinations according to the invention of compounds of the formula I and formula VI or analogues thereof and metabolites thereof are suitable for the treatment of neoplasms. Combination therapy can be carried out alone or in combination with another therapy (for example operation, irradiation, chemotherapy, biological therapy). In addition, a person whose risk of developing a neoplasm is greater (for example someone who is genetically predisposed or someone who previously had a neoplasm) can be given prophylactic treatment in order to inhibit or delay neoplasm formation.

The invention likewise relates to the combination of kinesin ATPase Eg5/KSP with the compounds of the formula VI, pentamidine, analogues thereof and/or metabolites thereof.

5

The dosage and frequency of administration of each compound in the combination can be controlled independently. For example, one compound may be administered orally three times daily, while the second compound may be administered intramuscularly once per day. The compounds may also be formulated together, leading to administration of both compounds.

10

15

The antiproliferative combinations according to the invention can also be provided as components of a pharmaceutical package. The two medicaments can be formulated together or separately and in individual dosage amounts.

20

Under another aspect, the invention encompasses a for the treatment of a patient who has a neoplasm, such as a cancer, by administration of a compound of the formula (I) and (VI) in combination with an antiproliferative agent. Suitable antiproliferative agents encompass those provided in Table 1.

25

Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means: if necessary, water is added, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. Rf values on silica gel; eluent: ethyl acetate/methanol 9:1.

30

35


Mass spectrometry (MS): EI (electron impact ionisation) M^+

FAB (fast atom bombardment) $(M+H)^+$

ESI (electrospray ionisation) $(M+H)^+$


5 APCI-MS (atmospheric pressure chemical ionisation – mass spectrometry) $(M+H)^+$

Example 1



a. Reaction in the presence of trifluoroacetic acid (TFA)

Example 2



35 4-Trifluoromethylaniline (145 mg, 0.9 mmol) is dissolved in 1.5 ml of acetonitrile, and TFA is added. 1,4-Dioxane (76.1 mg, 0.9 mmol) and benzaldehyde (0.09 ml, 0.9 mmol) are initially introduced in 1.5ml of ACN, then the 4-trifluoromethylaniline TFA salt in acetonitrile is added rapidly at

26474-1066

- 78 -

room temperature. The reaction mixture is stirred overnight at RT. The solvent is removed. The purification is carried out by chromatography. The two isomers obtained can be separated.


- 5 The two racemic mixtures can be separated into the corresponding enantiomers by chiral HPLC.

$[M^{++1}] = 336$

- 10 The following compounds according to the invention are obtained analogously using or corresponding precursors:


15

I1



20


I2



25

30

I3







Chiral

35

26474-1066

- 79 -




26474-1066

- 80 -


5

I8



10


I9



15


20

I10



25


I11



30

35

I12




26474-1066

- 81 -


5

I13



10


I14



15

20


I15



25

30

I16




26474-1066

- 82 -


5

I17



10


I18



15


20

I19



25

I20




30

26474-1066

- 83 -


5

I21




10

I22



15


I23



20

25

I24




30

26474-1066

- 84 -


5

I25




10

I26



15


I27



20

25

I28




30

35


5

I29



10


I30



15


20

I31




25

I32



30


35




26474-1066

- 87 -


5



10




15




20


25




I44




I45




I46




I47





152


5



10

153


15



20




154

25




30


35




158










159



160








25

30

35


5

I68




10

I69



15


I70



20

25


I71




30

35


172




173



174




175



5


176



10

15


177



20


25

178











30





179



35








5

I92


10



15

I93


20



25


I94

30




35


I95



I96




I97



I98


5



I99

10


15



20

I100

25




30

35

5


I101



10

15


I102



20

25

I103




30

35


I104

5




10

I105



15


I106



20

I107


25




30

35


I108




I109




I110



I111




I112




5

I113




10

I114



15

I115




20

25

30


35

I116



5


I117



10


15

I118



20


I119



25

30

I120




35

I121


5

10




I122

15



I123

20




I124

25


30

35



5


I125



10


15

I126




20

I127



25


I128



35

I129


5



I130

10


15



I131

20


25



I132


30

35




5

I133




10

I134



15

I135




20

25

30


I136



35

5


I137



10


15

I138




20

I139



25

I140




30

35


5

I141



10


I142



15

20


I143



25

30


I144



35

5


I145



10

15


I146



20


25

I147



30


I148



35

5


I149



10


15

I150



20


I151



25

30


I152



35

5


I153



10


15

I154




20

I155




25

I156



30


I157



35


5

I158



10


I159



15

20


I160



25

30


I161



35


5

I162



10


I163



15

20


I164



25


30

I165




35


I166




I167




I168



I169




I170




5

I171




10

I172



15

I173




20

25

30


I174



35

5


I175



10


15

I176



20


I177



25

30


I178



35

5


I179



10


15

I180



20


I181



25

30


I182



35


I183

5



I184


15



I185

20


25



I186


30

35




5

I187



10


I188



15

20


I189



25

30

I190




35

26474-1066

- 127 -


5

I191




10

I192



15


I193



20

25

I194



30


35

I195

26474-1066


- 128 -

5




10

I196



15


I197



20


25

I198



30


I199



35


5

I200




10

I201



15


I202



20


25

I203



30


I204



35


5

I205




10

I206



15


I207



20


25

I208



30

I209




35

26474-1066

- 131 -


5

I210




10

I211



15


I212



20


25

I213



30


I214



35


5

1215



10


1216



15

20


1217



25

30

1218




35

26474-1066

- 133 -


I219

Chiral




I220

Chiral




I221

CH



I222

Chiral




26474-1066

- 134 -


5

I223




10

I224



15


I225



20

25

I226




30

26474-1066


- 135 -

I227



5


I228



10

15

I229




20

ClH

25

I230




30

26474-1066

- 136 -

Chiral


I231



5


Chiral

I232




10

I233



20

I234



30

35

Example A: Assay I

5 The efficacy of the compounds according to the invention can be determined, for example, via the Eg5 ATPase activity, which is measured via an enzymatic regeneration of the product ADP to ATP by means of pyruvate kinase (PK) and subsequent coupling to an NADH-dependent lactate dehydrogenase (LDH) reaction. The reaction can be monitored via the change in absorbance at 340 nm by coupling to the NADH-dependent
10 LDH. The regeneration of the ATP simultaneously ensures that the substrate concentration remains constant. The change in absorbance per time unit are analysed graphically and a linear regression carried out in the visually linear region of the reaction.

15

Example B: Assay II

20 The combination of the antiprotozoic pentamidine and the inhibitors of kinesin ATPase Eg5/KSP results in increased inhibitory effects in cell proliferation tests with the colon carcinoma cell line HCT116.

Eg5 inhibitors adversely affect the ATPase activity and inhibit the course of the cell cycle owing to an error in the separation of the spindle poles.

25

The determination of the efficacy of the compounds of the formula I according to the invention in combination with compounds of the formula VI and/or medicaments from Table I can be demonstrated as follows in combination assays:
30

10³ to 10⁴ cells of a defined cell line (HCT116, Colo 205, MDA-MB 231, etc.) are sown into each well of a 96-well microtitre plate and cultivated overnight under standard conditions. For the substances of the combination to be tested, 10-50 mM stock solutions in DMSO were prepared. Dilu-
35

tion series (generally 3-fold dilution steps) of the individual substances were combined with one another in the form of a pipetting scheme (see scheme below), while maintaining a DMSO final concentration of 0.5% (v/v). Next morning, the substance mixtures were added to the cells, which
5 were incubated under culture conditions for a further 48 hours. At the end of the cultivation, Crystal Violet staining of the cells was carried out. After extraction of the Crystal Violet from the fixed cells, the absorption at 550 nm was measured spectrophotometrically. It can be used as a quantitative
10 measure of the adherent cells present.

15

20

25

30

35

Scheme

5

10

15

20

Is
ula

↑

Compounds of the formula I

←

	1	2	3	4	5	6	7	8	9	10	11	12
A		81 y	27 y	9 y	3 y	y	0					
B	81 x								empty	empty	empty	
C	27 x								0.5% DMS O	0.5% DMS O	0.5% DMS O	
D	9 x											
E	3 x											
F	x											
G	0											
H												

Example C: Injection vials

A solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.

Example D: Suppositories

A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

Example E: Solution

5 A solution is prepared from 1 g of an active ingredient of the formula I,
9.38 g of $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$, 28.48 g of $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$ and 0.1 g of
benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to
6.8, and the solution is made up to 1 l and sterilised by irradiation. This so-
lution can be used in the form of eye drops.

10

Example F: Ointment

500 mg of an active ingredient of the formula I are mixed with 99.5 g of
15 Vaseline under aseptic conditions.

Example G: Tablets

20 A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose,
1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is
pressed in a conventional manner to give tablets in such a way that each
tablet contains 10 mg of active ingredient.

25

Example H: Dragees

Tablets are pressed analogously to Example E and subsequently coated
in a conventional manner with a coating of sucrose, potato starch, talc,
30 tragacanth and dye.

35

Example I: Capsules

5 2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.

Example J: Ampoules

10 A solution of 1 kg of active ingredient of the formula I in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

15

20

25

30


35

26474-1066

- 142 -

CLAIMS:

1. A compound of formula I



in which

- 5 W is CH or N;

R¹ is H, A, (CY₂)_n-SA, -(CY₂)_n-SCF₃, -(CY₂)_n-SCN, -(CY₂)_n-CF₃, -(CY₂)_n-OCF₃, cycloalkyl, -(CY₂)_n-OH, (CY₂)_n-CN, -(CY₂)_n-Hal, (CY₂)_n-OA, or -(CY₂)_n-NHCOA;

- R² and R³, independently of one another, are each H, A, aryl, heteroaryl, Hal, -(CY₂)_n-SA, -(CY₂)_n-SCF₃, -(CY₂)_n-SCN, -(CY₂)_n-CF₃, -(CY₂)_n-OCF₃,
 10 cycloalkyl, -SCH₃, -SCN, -CF₃, -OCF₃, -OA, -(CY₂)_n-OH, -(CY₂)_n-CO₂R, -(CY₂)_n-CN, -(CY₂)_n-Hal, -(CY₂)_n-NR₂, (CY₂)_n-OA, (CY₂)_n-OCHOA, -SCF₃, (CY₂)_n-CONR₂-(CY₂)_n-NHCOA, or -(CY₂)_n-NHSO₂A;

Y is H, A, or Hal;

A is alkyl;

- 15 Hal is F, Cl, Br or I;

R is H or A, in the case of geminal radicals R together also -(CH₂)₅- or -(CH₂)₄-;

R⁴ and R⁵ together are -X(CH₂)₂X-, -XCH(CH₂OR)CR₂X-, -XCR₂CH(CH₂OR)X-, -XCH(CH₂NR₂)CR₂X- or -XCR₂CH(CH₂NR₂)X-;

- 20 X is O;

26474-1066

- 143 -

R^6 is aryl or heteroaryl, each of which is unsubstituted or mono- or polysubstituted by aryl or heteroaryl, each of which may be substituted by Hal, NO_2 , CN, A, OR, OCOR, NR_2 , CF_3 , OCF_3 or $OCH(CF_3)_2$, or by Hal, NO_2 , CN, OR, A, $-(CY_2)_n-OR$, $-OCOR$, $-(CY_2)_n-CO_2R$, $-(CY_2)_n-CN$ or $-(CY_2)_n-NR_2$;

5 R^7 is $(C=O)-R$, $(C=O)-NR_2$, $(C=O)-OR$, H or A; and

n and m, independently of one another, are each 0, 1, 2, 3, 4, 5, 6 or 7,

or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios.

2. A compound according to claim 1, or a pharmaceutically usable solvate,
10 tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^1 is A, CF_3 , OCF_3 , SA, SCN, CH_2CN , Hal, SCF_3 , t-butyl, $-CH(CH_3)CH_2CH_3$, isopropyl, ethyl or methyl.

3. A compound according to claim 1, or a pharmaceutically usable solvate,
15 tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^2 is F or H.


4. A compound according to claim 1, or a pharmaceutically usable solvate,
tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^3 is F or H.

5. A compound according to claim 1, or a pharmaceutically usable solvate,
20 tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^4 and R^5 together are $-X(CR_2)_2X-$.


6. A compound according to claim 1, or a pharmaceutically usable solvate,
tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^5 together with R^4 has one of the following meanings:

26474-1066

- 144 -








7. A compound according to claim 1, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^6
- 5 is phenyl, 2-, 3- or 4-pyridyl, pyrimidyl, furyl or thienyl, which in each case is unsubstituted or mono- or polysubstituted by Hal, CN, NO_2 , OH, CF_3 , $OCH(CF_3)_2$, $OCOCH_3$ or A.
8. A compound according to claim 1, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^6
- 10 is one of the following groups:





26474-1066

- 145 -




5




26474-1066

- 146 -



9. A compound according to claim 1, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, in which R^7 is H.

10. A compound according to claim 1, wherein said compound is of sub-formula IA:





10 or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, wherein R^8 is H, CH_2OR or CH_2NR_2 .

11. A compound according to claim 1, wherein said compound is of formulae A and B:

26474-1066


- 147 -



the racemate thereof or other mixtures of the enantiomers.

12. A compound according to claim 1, wherein said compound is of sub-
5 formulae I1 to I43:


I1




26474-1066

- 148 -


11a




12




12a




13



13a




14




26474-1066

- 149 -


15




16




17




17a



18




18a




26474-1066

- 150 -


I9




I9a




II0




II1



II1a




II2




26474-1066

- 151 -


II3




II3a




II4



II5




II6




26474-1066


- 152 -




II6a




II7




II8



II8a




II9




II9a

26474-1066


- 153 -




I20




I21



I21a



I22




I23


26474-1066

- 154 -


I24




I24a




I25



I26




I27




26474-1066

- 155 -


I27a




I29




I29a



I30




I30a




26474-1066

- 156 -


I31




I31a




I32



I32a




I33




26474-1066

- 157 -


I33a




I34




I34a



I35




I35a




26474-1066


- 158 -




B36




B36a




B37



B37a



B38




B39


26474-1066

- 159 -


I40




I40a



I41




I41a




26474-1066

- 160 -


I42



I42a, or



I43




or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios.

13. A process for the preparation of a compound of formula I according to claim 1, said process comprising:


reacting a compound of formula II

26474-1066

- 161 -




with a compound of formula III



and with a compound of the following formula, the double-bond isomer (E isomer)

5 thereof or mixtures thereof



and, optionally, a radical R^7 which is H in a compound of formula I is converted into a radical R^7 which has a meaning other than H, and/or, optionally, a base or acid of the formula I is converted into one of its salts.

10 14. A process according to claim 13, wherein the reaction is carried out in the presence of a protonic acid or Lewis acid.


15. A process according to claim 13, wherein the reaction is carried out in the presence of trifluoroacetic acid, hexafluoroisopropanol, bismuth(III) chloride, ytterbium(III) triflate, scandium(III) triflate or cerium(IV) ammonium nitrate.

15 16. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 12, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, and at least one excipient and/or adjuvant.

26474-1066

- 162 -

17. A mixture comprising one or more compounds according to any one of claims 1 to 12, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, and an amount of one or more compounds of formula VI:




in which

Y' and Z' each, independently of one another, are O or N,

R^{7'} and R^{9'} each, independently of one another, are H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂,

10 p is an integer between 2 and 6, each inclusive, and

R^{6'} and R^{8'} are each, independently of one another, in the meta- or para-position and are selected from:



15 18. A mixture according to claim 17, where the compound of formula VI is pentamidine or a salt thereof.


26474-1066

- 163 -

19. Use of a compound according to any one of claims 1 to 12, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, or a mixture according to claim 17 or 18, for the preparation of a medicament for the treatment of a disease which is influenced by the inhibition,
5 regulation and/or modulation of the mitotic motor protein Eg5.
20. Use of a compound according to any one of claims 1 to 12, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, or a mixture according to claim 17 or 18 for the preparation of a medicament for the treatment and prophylaxis of a cancer disease.
- 10 21. The use according to claim 20, where the cancer disease is accompanied by a tumour from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of
15 the lung.
22. The use according to claim 21, where the tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma.
23. The use according to claim 20, where the cancer disease to be treated
20 is a tumour of the blood and immune system.
24. The use according to claim 23, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
25. Use of a compound according to any one of claims 1 to 12 and/or a
25 physiologically acceptable salt or solvate thereof for the preparation of a medicament for the treatment of a tumour in combination with a therapeutically effective amount of one or more compounds of the formula VI:


26474-1066

- 164 -



in which

- Y' and Z' each, independently of one another, denote O or N, R^{7'} and R^{9'} each, independently of one another, denote H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂, p denotes an integer between 2 and 6, each inclusive, and R^{6'} and R^{8'} are each, independently of one another, in the meta- or para-position and are selected from the group:



10 where

the compound according to any one of claims 1 to 12 and/or a physiologically acceptable salt or solvate thereof, and the compound of the formula VI are for administration simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of a tumour or of other hyperproliferative cells.

26. The use according to claim 25, where the compound of the formula VI used is pentamidine or a salt thereof.

26474-1066

- 165 -


27. Use of a compound according to any one of claims 1 to 12 and/or a physiologically acceptable salt or solvate thereof for the preparation of a medicament for the treatment of a tumour where a therapeutically effective amount of the compound is for administration in combination with radiotherapy and a compound
5 from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.
28. Use of a compound according to any one of claims 1 to 12, or a
10 pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, or a mixture according to claim 17 or 18, for the treatment of a disease which is influenced by the inhibition, regulation and/or modulation of the mitotic motor protein Eg5.
29. Use of a compound according to any one of claims 1 to 12, or a
15 pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture thereof in any ratios, or a mixture according to claim 17 or 18 for the treatment and prophylaxis of a cancer disease.
30. The use according to claim 29, where the cancer disease is accompanied by a tumour from the group of tumours of the squamous epithelium, of
20 the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.
31. The use according to claim 30, where the tumour originates from the
25 group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma.
32. The use according to claim 29, where the cancer disease to be treated is a tumour of the blood and immune system.

26474-1066

- 166 -


33. The use according to claim 32, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

34. Use of a compound according to any one of claims 1 to 12 and/or a
5 physiologically acceptable salt or solvate thereof for the treatment of a tumour in combination with a therapeutically effective amount of one or more compounds of the formula VI:



in which

10 Y' and Z' each, independently of one another, denote O or N, R^{7'} and R^{9'} each, independently of one another, denote H, OH, halogen, OC1-10-alkyl, OCF₃, NO₂ or NH₂, p denotes an integer between 2 and 6, each inclusive, and R^{6'} and R^{8'} are each, independently of one another, in the meta- or para-position and are selected from the group:



where

26474-1066

- 167 -

the compound according to any one of claims 1 to 12 and/or a physiologically acceptable salt or solvate thereof, and the compound of the formula VI are for administration simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of a tumour or of other hyperproliferative
5 cells.

35. The use according to claim 34, where the compound of the formula VI used is pentamidine or a salt thereof.

36. Use of a compound according to any one of claims 1 to 12 and/or a physiologically acceptable salt or solvate thereof for the treatment of a tumour where
10 a therapeutically effective amount of the compound is for administration in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase
15 inhibitor and 10) further angiogenesis inhibitors.

37. The pharmaceutical composition according to claim 16 for use in the treatment of a disease which is influenced by the inhibition, regulation and/or modulation of the mitotic motor protein Eg5.

38. The pharmaceutical composition according to claim 16 for use in the
20 treatment and prophylaxis of a cancer disease.

39. The pharmaceutical composition according to claim 38, where the cancer disease is accompanied by a tumour from the group of tumours of the squamous epithelium, of the bladder, of the stomach, of the kidneys, of head and neck, of the oesophagus, of the cervix, of the thyroid, of the intestine, of the liver, of
25 the brain, of the prostate, of the urogenital tract, of the lymphatic system, of the stomach, of the larynx and/or of the lung.

26474-1066

- 168 -

40. The pharmaceutical composition according to claim 39, where the tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma and colon carcinoma.

5 41. The pharmaceutical composition according to claim 38, where the cancer disease to be treated is a tumour of the blood and immune system.

42. The pharmaceutical composition according to claim 40, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.

10 43. The pharmaceutical composition according to claim 16 for use in the treatment of a tumour where a therapeutically effective amount of the compound is for administration in combination with radiotherapy and a compound from the group
1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase
15 inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.

44. The mixture according to claim 17 or 18 for use in the treatment of a tumour, wherein the compound according to any one of claims 1 to 12, or a pharmaceutically usable solvate, tautomer, salt or stereoisomer thereof, or a mixture
20 thereof in any ratios, and the compound of the formula VI are for administration simultaneously or within 14 days of one another in amounts which are sufficient to inhibit the growth of a tumour or of other hyperproliferative cells.

